CAR-T cells : new developments and implications in lymphoma

Recently, the use of chimeric antigen receptor modified T cells or CAR-T cells has emerged in the therapeutic arsenal of several hematological pathologies, including lymphoma. These CAR-T are the product of extensive research on understanding the mechanisms of tumour immunity and are the product of cellular engineering. By combining the specific recognition of an antibody and the activation pathways of a cytotoxic cell, CAR-T cells allow promising clinical results, but they also see the occurrence of side effects that are more specific to these traetments, which it is essential to manage in a multidisciplinary team. The trail that have enabled their use differ on many points, including patient selection, the manufacture of the CAR or the pre-therapeutic conditioning. In the future, the use of this expensive therapy could be extended to other lymphomas and new generations of CAR-T cells could emerge.